Yüklüyor......

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas

BACKGROUND: Immunotherapy has demonstrated encouraging clinical benefits in patients with advanced breast carcinomas and Programmed death ligand 1 (PD-L1) expression has been proposed as an immunotherapy biomarker. Challenges with current PD-L1 testing exist and tumor mutation burden (TMB) is emergi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diagn Pathol
Asıl Yazarlar: Mei, Ping, Freitag, C. Eric, Wei, Lai, Zhang, Yunxiang, Parwani, Anil V., Li, Zaibo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212599/
https://ncbi.nlm.nih.gov/pubmed/32393302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13000-020-00971-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!